Conditions
CLL, Leukaemia, Chronic Lymphocytic, Leukaemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic, SLL, Small-Cell Lymphoma
Trial Purpose
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukaemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
NATIONAL TRIAL REFERENCE NUMBER
NCT05947851
EU CT
2022-501560-17-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
About The Trial
All patients who enroll in the trial will receive medication while on the study.
In part 1, all patients will receive nemtabrutinib and venetoclax
In part 2, 50% of patients will receive nemtabrutinib and venetoclax
In part 2, 50% of patients will receive venetoclax and rituximab
Trial Phase
Trial Phase 3
Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or doctors’ offices.
Trial start and end dates
- Actual study start date 8 August 2023
- Estimated primary completion date 27 June 2033
- Estimated study completion date 27 June 2033
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about